Axsome Therapeutics
AXSM
35 hedge funds and large institutions have $12.2M invested in Axsome Therapeutics in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 8 closing their positions.
78% more call options, than puts
Call options by funds: $16K | Put options by funds: $9K
0% more funds holding
Funds holding: 35 → 35 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
2.51% less ownership
Funds ownership: 15.97% → 13.46% (-2.5%)
7% less capital invested
Capital invested by funds: $13.1M → $12.2M (-$932K)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
+$820K |
| 2 |
SCM
Sio Capital Management
New York
|
+$661K |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$282K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$188K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$119K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.68M |
| 2 |
RA
Royce & Associates
New York
|
-$1.65M |
| 3 |
JP Morgan Chase
New York
|
-$121K |
| 4 |
Barclays
London,
United Kingdom
|
-$117K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$69K |
AXSM Hedge Fund Activity: Q3 2018 in Review
35 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q3 2018, worth a combined $12.2M — down 7.1% from $13.1M a quarter earlier.
Fund positioning in AXSM was balanced in Q3 2018: 8 funds opened new positions, 8 closed out, 6 added to existing stakes and 9 trimmed.
The largest buyer was Alethea Capital Management, adding an estimated $820K. The largest seller was Fidelity Investments, cutting an estimated $1.68M.
- 35 institutional investors held Axsome Therapeutics (AXSM) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $12.2M of Axsome Therapeutics stock for Q3 2018, down 7.1% quarter-over-quarter.
- 8 funds opened new Axsome Therapeutics positions in Q3 2018 and 8 closed out, a net change of 0 holders.
- The largest Axsome Therapeutics buyer in Q3 2018 was Alethea Capital Management, an estimated $820K added.
- The largest Axsome Therapeutics seller in Q3 2018 was Fidelity Investments, an estimated $1.68M sold.
Based on aggregated 13F filings for Q3 2018.